PhRMA Study Puts 340B Markups at $142 Billion
A research report released by PhRMA estimates that markups on 340B drugs cost patients and insurers billions of dollars each year.
Updated on Nov. 16, 2026 in Healthcare

Live Poll
Do you think federal drug discount programs are actually lowering what you pay?
PhRMA released research from Berkeley Research Group estimating that markups on drugs purchased under the 340B program cost patients and insurers billions annually. Patients and insurers paid $244 billion in 2025 for 340B drugs.
Why it matters
The 340B program was enacted in 1992 to broaden medication access for low-income individuals, and roughly sixty percent of hospitals now participate. The research attributes the markups to a lack of constraints written into the program.
Patients and insurers paid $244 billion in 2025 for 340B drugs, while providers paid $102.1 billion to acquire them, a $142 billion annual markup. The estimate comes from a PhRMA-released study, and the extraction does not detail its full methodology.
The players
PhRMA
The Pharmaceutical Research and Manufacturers of America is the trade association representing major drug manufacturers in the United States.
Berkeley Research Group
Berkeley Research Group is a global consulting firm that produces economic and financial analysis for corporate and public clients.
The details
Berkeley Research Group produced the report for PhRMA, estimating payments by patients and insurers against provider acquisition costs for 340B drugs. The research further estimates that markups cost Virginian employers $146 million in health care costs and led to $12.1 million in lost state and local tax revenue in Virginia.
Timeline
- The 340B program was enacted in 1992.
- Patients and insurers paid $244 billion for 340B drugs in 2025.
- The estimated $142 billion annual markup recurs each year, according to the research.
Market Landscape
The 340B Drug Pricing Program, enacted in 1992 to broaden medication access for low-income patients, now covers roughly sixty percent of U.S. hospitals. This PhRMA-released research places the program's pricing gap at the center of a debate over how its benefits are distributed.
Patients and insurers bear the cost of 340B markups through the prices they pay for drugs, which the research estimates totals $142 billion each year. Employers in states such as Virginia may see higher health care costs as a result.
The takeaway
Drug prices paid by patients and insurers can diverge sharply from what providers pay to acquire them, so it is worth checking how a prescription is priced and covered. The figures in this report come from a PhRMA-released study, and readers may wish to weigh them alongside other analyses.
Further reading
For related coverage, see Healthcare industry news.
Source note: This article includes information reported by News/Talk 960-AM & FM-107.3 WFIR.
Live Poll
Do you think federal drug discount programs are actually lowering what you pay?










